Home › Mieloma multiplo › Virginia
Studi clinici su Mieloma multiplo nello stato di Virginia
20 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Virginia.
Città nello stato di Virginia
Testo ufficiale dello studio (inglese)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gainesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07391657A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Virginia Commonwealth University - Massey Cancer Center, Richmond
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Charlottesville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07073547A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Alexander T. Augusta Military Medical Center, Fort Belvoir
- Virginia Oncology Associates Brock Cancer Center, Norfolk
- Richmond VA Medical Center, Richmond
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05552222A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
- Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Inova Schar Cancer Institute, Fairfax
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- VCU Massey Comprehensive Cancer Center, Richmond
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Oncology Associates, Norfolk
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06297226AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06106945AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlottesville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Fairfax
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Sovah Health Martinsville, Martinsville
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- e altri 2
In reclutamentoFase 3
Tutte le età · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Virginia Oncology Associates, Norfolk
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Virginia Oncology Associates, Norfolk
In reclutamentoFase 2
Età 19 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Fairfax
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Virginia Cancer Specialists, Fairfax
- Blue Ridge Cancer Center, Roanoke
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Virginia Commonwealth University, Richmond
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- NEXT Oncology Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2025 · NCT06119685Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.